Evidence map›Paper›PMID 37573408›Full record

ArticleOncogene2023

FANCA deficiency promotes leukaemic progression by allowing the emergence of cells carrying oncogenic driver mutations.

Patrycja Pawlikowska, Laure Delestré, Sebastian Gregoricchio, Alessia Oppezzo, Michela Esposito, M' Boyba Diop, Filippo Rosselli, Christel Guillouf

Open access · hybridAbstract read
In one paragraph

Article in Oncogene, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Patrycja Pawlikowska *CNRS UMR9019, Université Paris-Saclay, Gustave Roussy Cancer Campus, Villejuif, France.
Laure Delestré *Equipe Labellisée Ligue Nationale Contre le Cancer, Villejuif, France.
Sebastian GregoricchioEquipe Labellisée Ligue Nationale Contre le Cancer, Villejuif, France.ORCID http://orcid.org/0000-0001-9209-5403
Alessia OppezzoCNRS UMR9019, Université Paris-Saclay, Gustave Roussy Cancer Campus, Villejuif, France.
Michela EspositoEquipe Labellisée Ligue Nationale Contre le Cancer, Villejuif, France.
M' Boyba DiopEquipe Labellisée Ligue Nationale Contre le Cancer, Villejuif, France.
Filippo RosselliCNRS UMR9019, Université Paris-Saclay, Gustave Roussy Cancer Campus, Villejuif, France. filippo.rosselli@gustaveroussy.fr.ORCID http://orcid.org/0000-0003-1080-5745
Christel GuilloufEquipe Labellisée Ligue Nationale Contre le Cancer, Villejuif, France. christel.guillouf@gustaveroussy.fr.ORCID http://orcid.org/0000-0001-7013-3149
Inserm · FRCentre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leukaemia is caused by the clonal evolution of a cell that accumulates mutations/genomic rearrangements, allowing unrestrained cell growth. However, recent identification of leukaemic mutations in the blood cells of healthy individuals revealed that additional events are required to expand the mutated clones for overt leukaemia. Here, we assessed the functional consequences of deleting the Fanconi anaemia A (Fanca) gene, which encodes a DNA damage response protein, in Spi1 transgenic mice that develop preleukaemic syndrome. FANCA loss increases SPI1-associated disease penetrance and leukaemic progression without increasing the global mutation load of leukaemic clones. However, a high frequency of leukaemic FANCA-depleted cells display heterozygous activating mutations in known oncogenes, such as Kit or Nras, also identified but at low frequency in FANCA-WT mice with preleukaemic syndrome, indicating that FANCA counteracts the emergence of oncogene mutated leukaemic cells. A unique transcriptional signature is associated with the leukaemic status of FANCA-depleted cells, leading to activation of MDM4, NOTCH and Wnt/β-catenin pathways. We show that NOTCH signalling improves the proliferation capacity of FANCA-deficient leukaemic cells. Collectively, our observations indicate that loss of the FANC pathway, known to control genetic instability, fosters the expansion of leukaemic cells carrying oncogenic mutations rather than mutation formation. FANCA loss may contribute to this leukaemogenic progression by reprogramming transcriptomic landscape of the cells.

Indexed as

Fanconi Anemia Complementation Group A ProteinLeukemiaAnimalsHeterozygoteMiceMutationOncogenesFanca protein, mouseFanconi Anemia Complementation Group A Protein

Identifiers

PMID37573408
PMCPMC10491493
OpenAlexW4385783645

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.